Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01727869
Title Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals

Advanced Solid Tumor


Erlotinib + REGN1400

Cetuximab + REGN1400


Age Groups: adult
Covered Countries USA

No variant requirements are available.